newsfilter
← Latest News
Business Wire·

Forma Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

Development pipeline progressing to key upcoming clinical milestones Multiple-ascending dose (MAD) cohorts of FT-4202 Phase 1 trial in sickle cell disease completed; hemoglobin increased ≥ 1 g/dL in approximately 71% of patients and improved hemat